Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma

SIMPLE SUMMARY: Immune checkpoint inhibitors have been shown to improve survival in patients with advanced melanoma; however, a proportion of patients do not experience durable clinical benefit with these agents. Findings from a previous study suggested that the use of proton pump inhibitors while r...

Descripción completa

Detalles Bibliográficos
Autores principales: Homicsko, Krisztian, Dummer, Reinhard, Hoeller, Christoph, Wolchok, Jedd D., Hodi, F. Stephen, Larkin, James, Ascierto, Paolo A., Atkinson, Victoria, Robert, Caroline, Postow, Michael A., Re, Sandra, Paulucci, David, Dobler, Darin, Michielin, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9103038/
https://www.ncbi.nlm.nih.gov/pubmed/35565428
http://dx.doi.org/10.3390/cancers14092300

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9103038/
https://www.ncbi.nlm.nih.gov/pubmed/35565428
http://dx.doi.org/10.3390/cancers14092300

Ejemplares similares